# US 2020/0270608 A1 · Modulation of huntingtin expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0270608 A1
- Document ID: US20200270608A1
- Status: Published application
- Kind: A1
- Application number: 16/801,431
- Filed: 2020-02-26
- Published: 2020-08-27
- Earliest claimed: 2009-09-11
- Assignees: Ionis Pharmaceuticals, Inc.
- Applicants: Ionis Pharmaceuticals, Inc.
- Inventors: Gene Hung; C. Frank Bennett; Susan M. Freier; Holly Kordasiewicz; Lisa Stanek; Don W. Cleveland; Seng H. Cheng; Lamya Shihabuddin
- Web page: https://patentgrep.com/patent/US20200270608A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/10: for osteoporosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/11: Antisense
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/345: having at least two different backbone modifications
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.

## Claims

### Claim 1

A single-stranded modified oligonucleotide consisting of 18 linked nucleosides and having:
a gap segment consisting of eight linked deoxynucleosides;
a 5′ wing segment consisting of five linked nucleosides; and
a 3′ wing segment consisting of five linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment;
wherein each nucleoside of each wing segment comprises a 2′O-methoxyethyl sugar; and
wherein the nucleobase sequence of the oligonucleotide consists of the sequence recited in SEQ ID NO: 35,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The single-stranded modified oligonucleotide of claim 1, wherein at least one nucleoside comprises a modified nucleobase.

### Claim 3 (depends on 2)

The single-stranded modified oligonucleotide of claim 2, wherein the modified nucleobase is a 5-methylcytosine.

### Claim 4 (depends on 1)

The single-stranded modified oligonucleotide of claim 1, wherein each cytosine is a 5-methylcytosine.

### Claim 5 (depends on 1)

The single-stranded modified oligonucleotide of claim 1, wherein at least one internucleoside linkage is a modified internucleoside linkage.

### Claim 6 (depends on 1)

The single-stranded modified oligonucleotide of claim 1, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

### Claim 7 (depends on 4)

The single-stranded modified oligonucleotide of claim 4, wherein at least one internucleoside linkage is a modified internucleoside linkage.

### Claim 8 (depends on 4)

The single-stranded modified oligonucleotide of claim 4, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

### Claim 9 (depends on 1)

A composition comprising the single-stranded modified oligonucleotide or pharmaceutically acceptable salt thereof of claim 1 and at least one pharmaceutically acceptable carrier or diluent.

### Claim 10 (depends on 4)

A composition comprising the single-stranded modified oligonucleotide or pharmaceutically acceptable salt thereof of claim 4 and at least one pharmaceutically acceptable carrier or diluent.

### Claim 11 (depends on 6)

A composition comprising the single-stranded modified oligonucleotide or pharmaceutically acceptable salt thereof of claim 6 and at least one pharmaceutically acceptable carrier or diluent.

### Claim 12 (depends on 8)

A composition comprising the single-stranded modified oligonucleotide or pharmaceutically acceptable salt thereof of claim 8 and at least one pharmaceutically acceptable carrier or diluent.

### Claim 13 (depends on 1)

The single-stranded modified oligonucleotide of claim 1, which is capable of inhibiting huntingtin expression.

### Claim 14 (depends on 4)

The single-stranded modified oligonucleotide of claim 4, which is capable of inhibiting huntingtin expression.

### Claim 15 (depends on 6)

The single-stranded modified oligonucleotide of claim 6, which is capable of inhibiting huntingtin expression.

### Claim 16 (depends on 8)

The single-stranded modified oligonucleotide of claim 8, which is capable of inhibiting huntingtin expression.
